NCT06937788Terminated
Replication of the Heads Up Atopic Dermatitis Trial With Registry Data
Pragmatic Replication of the Heads Up Head-to-head Study of Upadacitinib and Dupilumab With TREATgermany Registry Data
Source: ClinicalTrials.gov · Last updated 28 Aug 2026
Reason given: Recruitment targets (sample size) could not be met within the planned time frame.
Brief summary (registry, in English)
The goal is the replication of the primary outcome (EASI 75 at week 16) of the Heads Up trial (Blauvelt, A, Teixeira, H, Simpson, E et al (2021) doi:10.1001/jamadermatol.2021.3023) and the evaluation of the patient reported outcomes (POEM, DLQI and RECAP) in a head-to-head comparison of upadacitinib versus dupilumab treatment in moderate-to-severe atopic dermatitis (AD).
- Status (registry)
- Terminated
- Study type
- Observational
- Enrollment
- 210 (actual)
- First submitted
- 14 Apr 2025
- Start date
- 2 Aug 2021
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Technische Universität Dresden
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06937788
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- contraindications according to upadacitinib or dupilumab labeling
Who the study is looking for
- Chronic AD with onset of symptoms at least 3 years prior to baseline
- Meets UK working party criteria
- EASI score ≥ 16
- ≥ 10% body surface area (BSA) of AD involvement at baseline ("therapy start") visit
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Evidence Based Health Care | Dresden | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.